Modern Vaccines Adjuvants & Delivery Systems

9-11 September 2019, Inselspital, Universitatsspital, Bern, Switzerland

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Provisional Conference Programme | Monday 9th September 2019


Moderator: Martin Bachmann
(Inselspital, University of Bern, Bern, Switzerland)

‘Improved adjuvants and delivery systems: A public health imperative’
Martin Friede
(WHO, Geneva, Switzerland)

‘Deep learning of vaccine adjuvant by machine and immunology’
Ken Ishii
(IMS/University of Tokyo, Tokyo, Japan)

‘NHP models for vaccines, adjuvants and delivery systems’
Ed Remarque
(BPRC, Rijiswijk, The Netherlands)

Coffee Break & Poster Set-Up


Moderator: Ken Ishii
(IMS/University of Tokyo, Tokyo, Japan)

‘Versatile particulate 20 nm quillaja adjuvant promotes both Th1 and Th2 responses to viral and bacterial antigens’
Bror Morein
(Uppsala University, Uppsala, Sweden)

‘An update on CAF01™ and the depot-or-not controversy revisited’
Dennis Christensen
(Statens Serum Institut, Copenhagen, Denmark)

‘The importance of IgA in protection against norovirus and influenza infections’
Sean Tucker
(Vaxart Inc., South San Francisco, California, USA)

‘Robust immunogenic response induced by highly transient Salmonella
Siegfried Hapfelmeier
(University of Bern, Bern, Switzerland)

Lunch Break & Posters


Moderator: Bror Morein
(Uppsala University, Uppsala, Sweden)

‘CAF08b a novel liposomal adjuvant which induces IgG2a class switching by acting directly on on B cells’
Gabriel Pedersen
(Statens Serum Institut, Copenhagen, Denmark)

‘Adjuvants targeting STING and inflammasomes for enhanced cellular immunity’
Edward Lavelle
(Trinity College Dublin, Dublin, Ireland)

‘Mucosal immunity evaluation for FLU vaccine’
Emanuele Montomoli
(VisMederi S.r.l., Siena, Italy)

‘T cell vaccination and immune regulation in cancer patients’
Daniel E. Speiser
(University of Lausanne, Epalinges, Switzerland)

Tea Break & Posters


Moderator: Edward Lavelle
(Trinity College Dublin, Dublin, Ireland)

‘Can the intranasal NanoVax™ adjuvant platform solve the enigma of suboptimal efficacy observed from intramuscular respiratory vaccines? RSV and flu vaccines revisited’
Ali Fattom
(BlueWillow Biologics, Ann Arbor, Michigan, USA)

‘Title to be confirmed’
Karl Ljungberg
(Eurocine Vaccines, Copenhagen, Denmark)

‘Title to be confirmed’
Bethany Girard
(EpiVax Inc., Providence, Rhode Island, USA)

‘Development of a vaccine against Type II diabetes’
Elisa Rösti
(Inselspital, Universty of Bern, Bern, Switzerland)

‘Developing adjuvants for animal vaccines: What do we have to consider?’
Jishu Shi
(Kansas State University, Manhattan, Kansas, USA)


MVADS 2019 Delegates

Login details will be supplied after you have registered for the event.

MVADS 2019 Sponsors

  • Vismederi
  • Alpha-O Peptides
  • BPRC
  • NIH
  • Janssen
  • Aldevron
  • Izon Science
  • Eurocine Vaccines
  • Croda
  • Desert King
  • Chemtrade
  • CureVac
  • Sequirus
  • Mymetics
  • IDRI
  • Bioaster
  • Sanofi Pasteur
  • Inovio Pharmaceuticals
  • EVI
  • BIA Separations
  • Seppic
  • Vaxart
  • Bencard Adjuvant Systems
  • Matrivax
  • Precision Vaccines Program
  • Verapido Medical

MVADS 2019 Downloads

MVADS 2019 Leaflet

MVADS 2019 Mailing List

E-mail Address
What is 3+2-1?